The wealth management firms New England Research & Management, Riverview Trust and Revolve Wealth Partners have recently invested in Thermo Fisher Scientific Inc. (TMO). Meanwhile, others such as Hennion & Walsh Asset Management, Artemis Investment Management, and Register Financial Advisors have reduced their holdings. TMO's stock is experiencing fluctuations, at times sinking as the market advances, while in other instances outshining market performance. Analysts from Barclays have sliced TMO's price target to $600.00. A SWOT insight into TMO points at strategic directions which could affect market performance. TMO's first quarter 2024 earnings showcased robust adjusted EPS, exceeding analyst expectations, while its stock has seen a significant increase of 40% over five months. TMO has launched new products to boost pDNA purification and has both introduced an innovative mass spectrometer and an automated plasmid purification system to assist in clinical research. Looking ahead, TMO has announced it will present at the BofA Securities 2024 Health Care Conference and host an Investor Day. Thermo Fisher's international revenue trends may prove an essential factor in assessing the stock.
Thermo Fisher Scientific TMO News Analytics from Thu, 14 Dec 2023 08:00:00 GMT to Sun, 30 Jun 2024 19:18:59 GMT -
Rating 1
- Innovation 3
- Information 6
- Rumor -2
